Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of WXFL10203614 tablets in moderate to severe active Crohn's disease
CTR20242140Phase 2Completed
- Sponsor
- Wuxi Fortune Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10203614 in Crohn's disease, sponsored by Wuxi Fortune Pharmaceutical Co., Ltd.. Started Oct 2024; status: completed.
02
Drugs
WXFL10203614
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20242140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242140.